Findings from a phase II #ClinicalTrial reveal that perioperative #Penpulimab + #Anlotinib provides promising efficacy and a manageable safety profile for resectable #NSCLC, identifying a potent new combination therapy.
#STTT #OpenAccess: doi.org/10.1038/s413...

A multicenter, open-label, randomized, phase II trial evaluating the efficacy and safety of perioperative #Penpulimab plus #Anlotinib with or without #Neoadjuvant #Chemotherapy, promising efficacy and a manageable safety profile in patients with resectable #NSCLC
#OpenAccess: doi.org/10.1038/s413...

An open-label, single-arm, phase II #ClinicalTrial assessing the efficacy of #Sintilimab + #Anlotinib revealed promising #AntiTumor effect and safety profile in treatment-naïve #Metastatic #ColorectalCancer (mCRC) patients.

#OpenAccess: doi.org/10.1038/s413...

An open-label, single-arm, phase II #ClinicalTrial of #Sintilimab + #Anlotinib in treatment-naïve #Metastatic #ColorectalCancer patients showed promising #Antitumor efficacy & a tolerable safety profile.

#STTT #OpenAccess: doi.org/10.1038/s413...

#Trametinib treatment results in the feedback activation of multiple #ReceptorTyrosineKinases (RTKs) and subsequent treatment with #Anlotinib effectively mitigates KRAS-mutant #NSCLC progression through the MEK/RTK-IGFBP2-RTK signaling loop.

#STTT #OpenAccess: doi.org/10.1038/s413...

Scientists report that #sintilimab plus #anlotinib demonstrates promising efficacy and manageable safety in treatment-naïve #mCRC, achieving an ORR of 48.3%, DCR of 89.7%, median PFS of 8.6 months, and OS of 22.9 months. #medsky

#FeaturedArticle in #STTT: doi.org/10.1038/s413...

This phase II trial demonstrated that #sintilimab plus #anlotinib exhibited preliminary #antitumor efficacy & a manageable safety profile as a #chemotherapy-free approach in treatment-naïve #MetastaticColorectalCancer. #medsky

Read in #STTT #OpenAccess: doi.org/10.1038/s413...

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC APOLLO trial shows that penpulimab plus anlotinib significantly improves survival outcomes over sorafenib in unresectable HCC.

New Paper Alert: APOLLO Trial. Anlotinib Plus Penpulimab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma

oncodaily.com/opinion/apol...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #APOLLO #Anlotinib #Penpulimab #Sorafenib #HCC

Novel ICI–TKI combination outplays sorafenib in advanced HCC First-line treatment with anlotinib plus penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to sorafenib.

#MedNews - First-line treatment with #anlotinib plus #penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to #sorafenib.

Full story 👉 buff.ly/aA3W8IV

#OncSky #HCC